NattoPharma, CARIM enter longterm R&D agreement
The agreement comes on the heels of a grant from the Dutch government to investigate effects of vitamin K supplementation on cardiovascular disease in patient and volunteer serum/plasma reflected by a biohybrid platform based on human vascular smooth muscle cells.
“This achievement confirms the success of NattoPharma's strategy to secure a substantial part of our product development and innovation project costs through public funding, grants and in collaboration with high-level scientific institutions," said Frode M. Bohan, chairman of the board of NattoPharma, in a statement.
NattoPharma already works with VitaK at the University of Maastricht. This collaboration resulted in the recently published three-year study demonstrating bone health and bone strength benefits of MenaQ7 Vitamin K2 in healthy post-menopausal women in Osteoporosis International. The new agreement with CARIM complements and expands NattoPharma’s R&D efforts.
